Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients

ABSTRACT

Background: This study provides a cost-effectiveness analysis of therapeutic strategies for chronic hepatitis C genotype 3 infected patients in Spain.

Methods: A Markov model was designed to simulate the progression in a cohort of patients aged 50 years over a lifetime horizon.

Results: Sofosbuvir (SOF) plus peginterferon and ribavirin for 12 weeks was a cost-effective option when compared to standard of care (SoC) in the treatment of both ‘moderate fibrosis’ and ‘cirrhotic’ patients. Incremental cost-effectiveness ratios were €35,276/QALY and €18,374/QALY respectively. ICERs for SOF plus daclatasvir (DCV) regimens versus SoC were over the threshold limit considered, at €56,178/QALY and €77,378/QALY for ‘moderate fibrosis’ and ‘cirrhotic’ patients respectively.

Conclusion: Addition of SOF to IFN-based regimens for genotype 3 was cost-effective for both ‘moderate fibrosis’ and ‘cirrhotic’ patients. IFN-free options including SOF and DCV association required price reductions lower than the list prices to be considered cost-effective.

KEYWORDS:

• Direct acting antivirals
• cost-effectiveness
• chronic hepatitis C
• daclatasvir
• disease-related costs
• pegylated interferon
• protease inhibitors
• ribavirin
• sofosbuvir
• treatment burden

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Supplemental data

Supplemental data for this article can be accessed here.

Additional information

Funding

This paper was not funded.